Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Farrugia (2002)
Risk of variant Creuzfeldt–Jakob disease from factor concentrates: current perspectivesHaemophilia, 8
E. Graf, E. Jander, A. West, H. Pora, H. Aranha-Creado (1999)
Virus removal by filtration.Developments in biological standardization, 99
P. Foster, A. Welch, C. Mclean, B. Griffin, J. Hardy, A. Bartley, S. MacDonald, A. Bailey (2000)
Studies on the Removal of Abnormal Prion Protein by Processes Used in the Manufacture of Human Plasma ProductsVox Sanguinis, 78
H. Brandwein, H. Aranha-Creado (2000)
Membrane filtration for virus removal.Developments in biologicals, 102
(1991)
Data Sheet . Millipore 9 / 1 / 2001 . 22 Viresolve NFR filters . Data Sheet
Tateishi Tateishi, Kitamoto Kitamoto, Lshikawa Lshikawa, Manabe Manabe (1993)
Removal of causative agent of Creutzfeldt‐Jakob disease (CJD) through membrane filtration methodMembrane, 18
JM Soucie, BH Robertson, BP Bell, KA McCaustland, BL Evatt (1998)
Hepatitis A virus infections associated with clotting factor concentrate in the United StatesTransfusion, 38
(1998)
Virus-filtration of factor IX – an approach to process validation
Douglas Lee, C. Stenland, Jeanette L.C. Miller, K. Cai, Elizabeth K. Ford, K. Gilligan, Randal Hartwell, Jarrett Terry, R. Rubenstein, M. Fournel, Stephen R. Petteway (2001)
A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteinsTransfusion, 41
Nora Hunter, F. Houston (2002)
Can prion diseases be transmitted between individuals via blood transfusion: evidence from sheep experiments.Developments in biologicals, 108
The use of Planova 35 filters in the production of hyperimmune plasma product
T. Burnouf, M. Radosevich (2001)
Affinity chromatography in the industrial purification of plasma proteins for therapeutic use.Journal of biochemical and biophysical methods, 49 1-3
P. Brown (2000)
BSE and transmission through bloodThe Lancet, 356
J. Eibl, N. Barrett, T. Hämmerle, F. Dorner (1996)
Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV.Biologicals : journal of the International Association of Biological Standardization, 24 3
T. Burnouf, M. Burnouf-Radosevich (1994)
Strategy of Virus Removal / Inactivation of Plasma-Derived Products : Interest of Nanofiltration as a New Virus Elimination Method
D. Evans (1997)
Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsyThe Lancet, 349
Y. Takeda, Akemi Wakisaka, K. Noguchi, T. Murozuka, Y. Katsubayashi, Shuzo Matsumoto, T. Tomono, Kusuya Nishioka (2001)
Receptor‐mediated haemagglutination screening and reduction in the viral load of parvovirus B19 DNA in immunopurified Factor VIII concentrate (Cross Eight M®)Vox Sanguinis, 81
K. Yamaguchi, Y. Hamamoto, S. Manabe, N. Yamamoto (1991)
Microparticle removability of the regenerated cellulose hollow fiber (BMM) : an electron microscopic evaluationJournal of Electron Microscopy, 40
F. Hong, R. Ruiz, H. Price, A. Griffiths, F. Malinoski, M. Woloski (1998)
Safety profile of WinRho anti-D.Seminars in hematology, 35 1 Suppl 1
L. Péjaudier, V. Kichenin-Martin, M. Boffa, M. Steinbuch (1987)
Appraisal of the Protein Composition of Prothrombin Complex Concentrates of Different OriginsVox Sanguinis, 52
Prowse (1997)
Human parvovirus B19 and blood productsVox Sang, 72
T. Burnouf, M. Radosevich (2000)
Reducing the risk of infection from plasma products: specific preventative strategies.Blood reviews, 14 2
(1996)
OMEGA VR TM virus reduction membrane. Element Data Sheet F1, Pall Corporation
F. Feldman, S. Chandra, C. Huang (1995)
Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine.Acta haematologica, 94 Suppl 1
(2002)
Virus and Application Filtration Guide
C. Gölker, M. Whiteman, K. Gugel, R. Gilles, P. Stadler, R. Kovatch, D. Lister, M. Wisher, C. Calcagni, G. Hübner (1996)
Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol.Biologicals : journal of the International Association of Biological Standardization, 24 2
J. Tateishi, T. Kitamoto, S. Mohri, S. Satoh, T. Sato, A. Shepherd, M. Macnaughton (2001)
Scrapie removal using Planova virus removal filters.Biologicals : journal of the International Association of Biological Standardization, 29 1
R. Bailey, M. Clarke (1989)
Patients undergoing surgery
H. Aranha-Creado, K. Oshima, S. Jafari, G. Howard, H. Brandwein (1997)
Virus retention by a hydrophilic triple-layer PVDF microporous membrane filter.PDA journal of pharmaceutical science and technology, 51 3
T. Yee, B. Cohen, K. Pasi, C. Lee (1996)
Transmission of symptomatic parvovirus B19 infection by clotting factor concentrateBritish Journal of Haematology, 93
D. Hilton, A. Ghani, Lisa Conyers, P. Edwards, L. McCardle, M. Penney, D. Ritchie, J. Ironside (2002)
Accumulation of prion protein in tonsil and appendix: review of tissue samplesBMJ : British Medical Journal, 325
M. Stucki, R. Moudry, C. Kempf, A. Omar, A. Schlegel, P. Lerch (1997)
Characterisation of a chromatographically produced anti-D immunoglobulin product.Journal of chromatography. B, Biomedical sciences and applications, 700 1-2
Factor VIII SD-35-15: Preliminary Results of a Cross-Over Pharmacokinetic Study of SD and 35-15 nm Filtered Factor VIII Concentrate Compared to Reference Product (SD Factor VIII Concentrate)). XVII
(2001)
FVIII SD - 35 - 15 , new safety standard for plasma - derived FVIII
(2001)
Improvements of viral safety in plasma derivatives by introduction of Planova filtration and its remaining problems
Rosendaal Rosendaal, Nieuwenhuis Nieuwenhuis, Van Den Berg Van Den Berg (1993)
A sudden increase in factor VIII inhibitor development in multitransfused hemophilia patients in The NetherlandsBlood, 81
Virus validation studies with the Planova Ò 15N filtration system and the determination of worst case conditions
M. Burnouf-Radosevich, T. Burnouf (1992)
Chromatographic Preparation of a Therapeutic Highly Purified von Willebrand Factor Concentrate from Human CryoprecipitateVox Sanguinis, 62
(1995)
validatable filter (BMM)
S. Manabe (1996)
Removal of virus through novel membrane filtration method.Developments in biological standardization, 88
M. Burnouf-Radosevich, T. Burnouf (1992)
A therapeutic, highly purified factor XI concentrate from human plasmaTransfusion, 32
Element Data Sheet F1
H. Tölö, H. Kauppinen, G. Alm, A. Perers, E. Lindeberg, V. Wahlstedt-Fröberg, J. Parkkinen (2001)
Development of a Highly Purified Multicomponent Leukocyte IFN-α ProductJournal of Interferon and Cytokine Research, 21
T. Burnouf, M. Burnouf-Radosevich, J. Huart, M. Goudemand (1991)
A Highly Purified Factor VIII:c Concentrate Prepared from Cryoprecipitate by Ion‐Exchange ChromatographyVox Sanguinis, 60
P. Brown, R. Rohwer, B. Dunstan, C. Macauley, D. Gajdusek, W. Drohan (1998)
The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathyTransfusion, 38
Thierry Burnouf (1993)
Chromatographic removal of viruses from plasma derivatives.Developments in biological standardization, 81
(1992)
The safety of IVIG preparations
P. Roberts (1995)
Value of Virus Filtration as a Method for Improving the Safety of Plasma ProductsVox Sanguinis, 69
M. Poulle, M. Burnouf-Radosevich, T. Burnouf (1994)
Large-scale preparation of highly purified human C1-inhibitor for therapeutic use.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 5 4
定美 関口, 敬三 伊藤, 正 小林, 久實 池田, 隆正 鶴見, 元 石川, 征一 真鍋, 佐谷 満洲夫, 駿 山敷 (1989)
再生セルロース中空糸 (BMM) を用いた人血漿からのB型肝炎ウイルス除去の可能性, 14
P. Brown (2001)
Transfusion medicine and spongiform encephalopathyTransfusion, 41
(2000)
vWF SD-35-DH: pharmacokinetic data and clinical efficacy. Plasma-Derived Medical Products and Haemostasis: Current Issues and Perspectives
K. Oshima, T. Evans-Strickfaden, A. Highsmith (1998)
Comparison of Filtration Properties of Hepatitis B Virus, Hepatitis C Virus and Simian Virus 40 Using a Polyvinylidene Fluoride Membrane FilterVox Sanguinis, 75
T. Tsurumi, N. Osawa, Hidetoshi Hitaka, T. Hirasaki, K. Yamaguchi, S. Manabe, Takashi Yamashiki (1990)
Structure of Cuprammonium Regenerated Cellulose Hollow Fiber (BMM Hollow Fiber) for Virus RemovalPolymer Journal, 22
A. Johnston, A. Macgregor, S. Borovec, M. Hattarki, K. Stuckly, D. Anderson, N. Goss, A. Oates, E. Uren (2000)
Inactivation and clearance of viruses during the manufacture of high purity factor IX.Biologicals : journal of the International Association of Biological Standardization, 28 3
(1996)
Evaluation of antiviral filters
Manabe Manabe, Tsurumi Tsurumi, Ishikawa Ishikawa (1989)
Mechanism of human immunodeficiency virus (HIV) removal by regenerated cellulose hollow fiber (BMM)Membrane, 14
(2003)
Annex 4 Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products
M. Azari, J. Boose, K. Burhop, T. Camacho, J. Catarello, A. Darling, A. Ebeling, T. Estep, L. Pearson, S. Guzder, J. Herren, K. Ogle, J. Paine, K. Rohn, R. Sarajari, C. Sun, L. Zhang (2000)
Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin crosslinked haemoglobin (DCLHb).Biologicals : journal of the International Association of Biological Standardization, 28 2
N. Troccoli, J. Mciver, A. Losikoff, J. Poiley (1998)
Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.Biologicals : journal of the International Association of Biological Standardization, 26 4
L. Bonsdorff, H. Tölö, E. Lindeberg, T. Nyman, A. Harju, J. Parkkinen (2001)
Development of a pharmaceutical apotransferrin product for iron binding therapy.Biologicals : journal of the International Association of Biological Standardization, 29 1
Nanofiltration, the EPFA experience
T. Burnouf, C. Michalski, M. Goudemand, J. Huart (1989)
Properties of a Highly Punified Human Plasma Factor IX:c Therapeutic Concentrate Prepared by Conventional ChromatographyVox Sanguinis, 57
R. Will, J. Ironside, M. Zeidler, S. Cousens, K. Estibeiro, A. Alpérovitch, S. Poser, M. Pocchiari, A. Hofman, Peter Smith (1996)
A new variant of Creutzfeldt-Jakob disease in the UKThe Lancet, 347
H. Tölö, H. Kauppinen, G. Alm, A. Perers, E. Lindeberg, V. Wahlstedt-Fröberg, J. Parkkinen (2001)
Development of a highly purified multicomponent leukocyte IFN-alpha product.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 21 11
D. Josić, L. Hoffer, A. Buchacher, H. Schwinn, W. Frenzel, L. Biesert, H. Klöcking, P. Hellstern, R. Rokicka‐Milewska, A. Klukowska (2000)
Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity.Thrombosis research, 100 5
F. Rosendaal, H. Nieuwenhuis, H. Berg, H. Heijboer, E. Bunschoten, J. Meer, C. Smit, P. Strengers, E. Briet (1993)
A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.Blood, 81 8
The use of Planova Ò 35 filters in the production of hyperimmune plasma product. Planova Ò Workshop USAÕ99. A Forum for Exchanging Information on the Latest Developments in Virus Removal Technology
(2002)
An overview of viral filtration in biopharmaceutical manufacturing
P. Mannucci, F. Tradati (1995)
Preliminary In Vivo Evaluation of a Nanofiltered Factor IX ConcentrateThrombosis and Haemostasis, 73
L. Hoffer, H. Schwinn, L. Biesert, D. Josić (1995)
Improved virus safety and purity of a chromatographically produced factor IX concentrate by nanofiltration.Journal of chromatography. B, Biomedical applications, 669 2
(1999)
Alpha-1 Proteinase Inhibitor (A1PI) Virus Reduction Studies
(2000)
Validation Guide VG-DV20, Pall ULTIPOR VF Grade DV20 AB style virus removal filter cartridges
(1998)
A bovine spongiform encephalopathy validation study for aprotinin and bovine serum albu
S. Manabe, Yukari Kamata, H. Iijima, K. Kamide (1987)
Some Morphological Characteristics of Porous Polymeric Membranes Prepared by “Micro-Phase Separation Method”Polymer Journal, 19
Sei-ichi Manabe, Takashi Tsurumi, Gen Ishikawa, Masuo Satani, Takashi Yamashiki, Yoshiaki Hamamoto, Kazuhito Yamaguchi, Susumu Kobayashi, Naoki Yamamoto (1989)
再生セルロース中空糸 (BMM) を用いたヒト免疫不全ウイルス (HIV) 除去機構, 14
M. Bruce, R. Will, J. Ironside, I. Mcconnell, D. Drummond, A. Suttie, L. McCardle, A. Chree, J. Hope, C. Birkett, S. Cousens, H. Fraser, C. Bostock (1997)
Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agentNature, 389
H. Abe, H. Sugawara, J. Hirayama, H. Ihara, T. Kato, H. Ikeda, K. Ikebuchi (2000)
Removal of Parvovirus B19 from Hemoglobin Solution by NanofiltrationArtificial Cells, Blood Substitutes, and Biotechnology, 28
J. Römisch, A. Gröner, D. Bernhardt, K. Diehl, B. Hein, W. List, H. Müller, T. Nowak, H. Ronneberger, E. Schüler, T. Weimer, J. Hilfenhaus (1996)
[Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality].Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine, 33
J. Goudemand, J. Peynet, H. Chambost, C. Négrier, M. Briquel, S. Claeyssens, A. Derlon-Borel, C. Guérois, C. Caron, J. Scherrmann, M. Debray, F. Bridey (1998)
A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX ConcentrateThrombosis and Haemostasis, 80
J. Tateishi, T. Tashima, T. Kitamoto (1991)
Practical Methods for Chemical Inactivation of Creutzfeldt‐Jakob Disease PathogenMicrobiology and Immunology, 35
潤 立石, 哲之 北本, 元 石川, 征一 真鍋 (1993)
クロイツフェルトヤコブ病 (CJD) の原因物質の膜除去方法, 18
J. Tateishi, Hitoka Doi, Y. Sato, Motohiro Suetsugu, K. Ishii, Yoshigoro Kuroiwa (2004)
Experimental transmission of human subacute spongiform encephalopathy to small rodentsActa Neuropathologica, 53
P. Brown, L. Cervenakova, L. McShane, P. Barber, R. Rubenstein, W. Drohan (1999)
Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt‐Jakob disease in humansTransfusion, 39
T. Burnouf (1995)
Chromatography in plasma fractionation: benefits and future trends.Journal of chromatography. B, Biomedical applications, 664 1
M. Burnouf-Radosevich, P. Appourchaux, J. Huart, Thierry Burnouf (1994)
Nanofiltration, a New Specific Virus Elimination Method Applied to High‐Purity Factor IX and Factor XI ConcentratesVox Sanguinis, 67
S. Schulman, R. Wallensten, B. White, O. Smith (1999)
Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgeryHaemophilia, 5
K. Peerlinck, J. Arnout, M. Giambattista, J. Gilles, R. Laub, M. Jacquemin, J. Saint-Remy, J. Vermylen (1997)
Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII ConcentrateThrombosis and Haemostasis, 77
R. Reis, A. Zydney (2001)
Membrane separations in biotechnology.Current opinion in biotechnology, 12 2
C. Prowse, C. Ludlam, P. Yap (1997)
Human Parvovirus B19 and Blood ProductsVox Sanguinis, 72
J. Tateishi, T. Kitamoto, H. Hiratani (1985)
CREUTZFELDT-JAKOB DISEASE PATHOGEN IN GROWTH HORMONE PREPARATIONS IS ELIMINATABLEThe Lancet, 326
J. Aubin, C. Defer, M. Vidaud, M. Montreuil, B. Flan (2000)
Large–Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for FractionationVox Sanguinis, 78
Tateishi Tateishi, Sato Sato, Koga Koga, Doi Doi, Ohta Ohta (1980)
Experimental transmission of human spongiform encephalopathy to small rodents. 1. Clinical and histopathological observationsActa Neuropathol, 51
Tsurumi Tsurumi, Osawa Osawa, Hitaka Hitaka (1990)
Structure of cuprammonium regenerated hollow fiber (BMM hollow fiber) for virus removalPolymer J, 22
J. Tateishi, T. Kitamoto, G. Ishikawa, S. Manabe, K. Yamaguchi (1995)
Filtration of PrP
(1999)
Normal prion protein is found in human plasma, but is removed by the SNBTS plasma fractionation process
Yasuo Kuroda, Clarence Gibbs, Herbert Amyx, D. Carleton, Gajdusek (1983)
Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytesInfection and Immunity, 41
Robert Will, R. Kimberlin (1998)
Creutzfeldt–Jakob Disease and the Risk from Blood or Blood ProductsVox Sanguinis, 75
Summary. This review presents the current status on the use and benefits of viral removal filtration systems – known as nanofiltration – in the manufacture of plasma‐derived coagulation factor concentrates and other biopharmaceutical products from human blood origin. Nanofiltration of plasma products has been implemented at a production scale in the early 1990s to improve margin of viral safety, as a complement to the viral reduction treatments, such as solvent–detergent and heat treatments, already applied for the inactivation of human immunodeficiency virus, hepatitis B and hepatitis C virus. The main reason for the introduction of nanofiltration was the need to improve product safety against non‐enveloped viruses and to provide a possible safeguard against new infectious agents potentially entering the human plasma pool. Nanofiltration has gained quick acceptance as it is a relatively simple manufacturing step that consists in filtering protein solution through membranes of a very small pore size (typically 15–40 nm) under conditions that retain viruses by a mechanism largely based on size exclusion. Recent large‐scale experience throughout the world has now established that nanofiltration is a robust and reliable viral reduction technique that can be applied to essentially all plasma products. Many of the licensed plasma products are currently nanofiltered. The technology has major advantages as it is flexible and it may combine efficient and largely predictable removal of more than 4 to 6 logs of a wide range of viruses, with an absence of denaturing effect on plasma proteins. Compared with other viral reduction means, nanofiltration may be the only method to date permitting efficient removal of enveloped and non‐enveloped viruses under conditions where 90–95% of protein activity is recovered. New data indicate that nanofiltration may also remove prions, opening new perspectives in the development and interest of this technique. Nanofiltration is increasingly becoming a routine step in the manufacture of biopharmaceutical products.
Haemophilia – Wiley
Published: Jan 1, 2003
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.